Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 29;20(4):987-990.
doi: 10.31557/APJCP.2019.20.4.987.

Small Centers with Big Ventures: Autologous Stem Cell Transplantation Survival Data

Affiliations

Small Centers with Big Ventures: Autologous Stem Cell Transplantation Survival Data

Muhammad Bilal Abid et al. Asian Pac J Cancer Prev. .

Abstract

We present the first-ever autologous stem cell transplantation (ASCT) outcome data from a secondary-care healthcare facility. Albeit exact details of patient and disease characteristics and co-morbidity scores for all patients are not available, the engraftment and survival data is very similar to those published from large tertiary-care cancer centres, both regionally and internationally. Transplant Related Mortality (TRM) of 3.1% is within the expected range and includes a patient who died of acute drug reaction (ADR) during conditioning chemotherapy, prior to the ASCT. Furthermore, cyclophosphamide mobilization chemotherapy is given in the outpatient setting. This study is important in terms of healthcare resource optimization as well as patients’ convenience and highlights that ASCT can be performed in a safe and effective manner with comparable survival rates even at a DGH, provided the centre stays abreast with the recent developments and can offer its patients with standard of care treatment of the era.

Keywords: Outcome analysis; autologous stem cell transplantation; district general hospital; secondary care center.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall Survival (OS) and Progression Free Survival (PFS) Data

Similar articles

References

    1. Abid MB, Christopher D, Abid MA, et al. Safety and cost-effectiveness of outpatient autologous transplantation for multiple myeloma in Asia: single-center perspective from Singapore. Bone Marrow Transplant. 2017;52:1044–6. - PubMed
    1. Ali N, Adil , SN , Shaikh MU. Autologous hematopoietic stem cell transplantation-10 years of data from a developing country. Stem Cells Transl Med. 2015;4:873–7. - PMC - PubMed
    1. Auner HW, Szydlo R, Hoek J, et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant. 2015;50:209–15. - PubMed
    1. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111:2521–610. - PubMed
    1. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Eng J Med. 2003;348:1875–83. - PubMed